Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis.

These findings suggest that tolvaptan 30 mg and 45 mg may be the optimum dosage for CHF patients, because of its ability to provide favourable clinical results without greater adverse effects. However, tolvaptan is not beneficial for reducing all-cause mortality in CHF patients.